Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yaoshan Qingwen oral spray is a Traditional Chinese Medicine (specifically Yao medicine) formulation developed by Beijing Yao Medicine Hospital for the treatment of COVID-19. It is primarily indicated for patients with asymptomatic or mild infections to accelerate the conversion of nucleic acid tests to negative (virologic clearance) and to reduce the risk of viral re-positivity after discharge. The drug is typically evaluated in clinical settings as part of a regimen that includes Yaoshan Qingwen Jiedu granules. As a botanical product, it likely exerts its effects through a combination of anti-inflammatory and antiviral properties inherent to its constituent herbs, targeting the upper respiratory tract to reduce viral load.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yaoshan Qingwen oral spray.